{"id":"W3088397291","doi":"10.1016/j.annonc.2020.08.004","title":"886MO Health-related quality of life (HRQoL) from KEYNOTE-204: A phase III, randomized, open-label study of pembrolizumab (pembro) vs brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma (R/R cHL)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital","funders":"Merck Sharp and Dohme","keywords":"Medicine; Quality of life (healthcare); Internal medicine; Health related quality of life; Population; Brentuximab vedotin; Pembrolizumab; Phases of clinical research; Stock options; Oncology; Surgery; Clinical trial; Cancer; Lymphoma; Hodgkin lymphoma; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001705901,0.00151102,0.002160395,0.0004540267,0.0004502289,0.001082585,0.0008666025,0.001433708,0.008461362],"category_scores_gemma":[0.0008597833,0.0006534047,0.001757812,0.0003609491,0.001128816,0.001075572,0.0005807165,0.004372505,0.001114159],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006580916,"about_ca_system_score_gemma":0.0008934247,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008057485,"about_ca_topic_score_gemma":0.001910757,"domain_scores_codex":[0.9995065,0.0002484351,0.00002290275,0.00006849142,0.0000413013,0.0001123536],"domain_scores_gemma":[0.9994736,0.0001394595,0.00009895707,0.00003605097,0.00002631997,0.0002254996],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9578812,0.01308923,0.001150112,0.000535696,0.0008603127,0.00003692446,0.00003959094,0.0004945445,0.005080429,0.00009692609,0.0009807297,0.01975438],"study_design_scores_gemma":[0.8932077,0.1011636,0.003379818,0.00002610633,0.0005711795,0.00003627456,0.00002510184,0.0003276639,0.0006692843,0.00008159596,0.0004986929,0.00001293716],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913504,0.002522968,0.0003473188,0.0004469143,0.000263104,0.001669631,0.001272426,0.00009844566,0.002028799],"genre_scores_gemma":[0.9903293,0.001565244,0.00105158,0.0008320666,0.0002887564,0.002082029,0.001700966,0.000021791,0.002128168],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008461362,"threshold_uncertainty_score":0.02830607,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2302915735254474,"score_gpt":0.4550039072882897,"score_spread":0.2247123337628423,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}